Certified by Founder
Lodge
Alveus Therapeutics Inc
start up
United States
- Philadelphia, Pennsylvania
- 09/01/2026
- Series A
- $160,000,000
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
- Industry Biotechnology Research
- Website https://alveustx.com/
- LinkedIn https://www.linkedin.com/company/alveus-therapeutics/
Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)